Kornimate/medical-research-clean huggingface dataset:
menstrual wellbeing in woman living in turkey; an epidemiological study

Conditions: Menstrual Problem; Quality of Life

Summary: women with endometriosis in our country and around the world face various difficulties during their menstrual periods in reproductive age. while some of these difficulties are caused by the environment, some of them are due to the insufficient development of personal consciousness. in our study, we aim to reveal the perspective of individuals and society on the menstrual period. our primary aim in our study is to understand what kind of problems are experienced in different regions of our country during the menstrual period for women and how they are spent. secondly, the effect of this period on women's quality of life will be examined.

our research will be conducted between january 1, 2022, and february 1, 2022, in 7 different regions of our country, by asking questions to women of reproductive age from different groups. each participant will be asked to answer the survey questions and the results will be analyzed. the survey will be done face to face. the questionnaire contains questions about women's socio-demographic data, their perspectives on their menstrual period, their information about endometriosis, and their perspectives on pads and birth control pills. menstruating women of reproductive age between the ages of 18- 45 will be included in this study. as a result of the study, the problems experienced by women of reproductive age in different regions will be evaluated.

Eligibility criteria:
inclusion criteria: * menstruating women of reproductive age between the ages of 18- 45 will be included in this study. exclusion criteria: * women with a history of hematological disease, cardiovascular disease, malignancy, advanced renal failure, active infection, diabetes mellitus, and pregnant women will not be included in the study.

Keywords: menstrual wellbeing reproductive age oral contraceptive endometriosis
the effect of acute normovolemic hemodilution in bone tumor surgery

Conditions: Acute Normovolemic Hemodilution; Bone Tumor; Goal-Directed Fluid Therapy; Transfusion

Summary: the prevention of intraoperative allogenetic blood transfusion has the potential to reduce complications, hospital stays, and long-term prognosis in patients undergoing bone tumor surgery. data from previous studies suggest that the clinical efficacy of acute normovolemic hemodilution (anh) has always been controversial, and intraoperative fluid administration strategy is an important confounding factor. the heal trial will assess whether anh will reduce the volume of intraoperative allogeneic red blood cell transfusion when applying goal-directed fluid therapy in patients undergoing bone tumor surgery.

bone tumor surgery is associated with a significant risk of perioperative blood loss and transfusion, with blood loss usually in the range of approximately 500-1000 ml and an average transfusion of up to 2 units of allogeneic red blood cell. the increase in allogeneic blood transfusion volume is an independent risk factor for postoperative complications in patients undergoing bone tumor surgery, as well as affecting the long-term survival rate of cancer patients. acute normovolemic hemodilution (anh) is a patient blood management measure. the clinical efficacy of acute normovolemic hemodilution (anh) has always been controversial, and intraoperative fluid administration strategy is an important confounding factor. as goal-directed fluid therapy (gdft) is increasingly used in clinical practice, it is of great importance to explore the efficacy of anh in patients undergoing fluid management using gdft. bone tumor surgery is an ideal setting to evaluate anh in gdft, as the procedure is associated with high blood loss and infusion. the 'hemodilution on intraoperative allogeneic transfusion' (heal) trial has been designed as a randomized, controlled trial to determine whether anh will reduce the volume of intraoperative allogeneic red blood cell transfusion when applying gdft in patients undergoing bone tumor surgery.

Eligibility criteria:
inclusion criteria: 1. age 18 to 75 years; 2. undergoing elective bone tumor resection surgery; 3. preoperative hemoglobin ≥11 g/dl; exclusion criteria: 1. using a tourniquet; 2. palliative operation or minimally invasive surgery; 3. bmi\ 30kg/m\^2; 4. international normalized ratio (inr) \>1.5 or platelet count \<100 × 10\^9/l; 5. cardiopulmonary insufficiency; 6. hepatic and renal dysfunction; 7. active infectious disease; 8. allergy to succinyl gelatin; 9. pregnancy; 10. declined participation in the study or declined blood transfusion
phase 2 study of association gemcitabine-cisplatin to treat penis epidermoid carcinoma

Conditions: Genital Neoplasms, Male

Summary: the purpose of this study is to determine whether association gemcitabine-cisplatin is effective in the treatment of penis epidermoid carcinoma loco-regionally advanced or metastatic.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * oms ≤ 2 * penis epidermoid carcinoma histologically proved. tumor with ganglionic loco-regional injury inextirpable and/or metastatic (m1, all t , all n), at initial diagnostic or at relapse after first treatment with curative aim (surgery and / or radiotherapy) * disease measurable with recist criteria * absence of all former chemotherapy during 5 years between inclusion. * if former radiotherapy, necessity to have appreciated targets outside the irradiation fields. if former radiotherapy, it must have been done more than 4 weeks before inclusion in the study. * biologicals values required : polynuclear neutrophils ≥ 1500/mm3, blood-platelets ≥ 100000/mm3, hb ≥ 10 g/dl, transaminases \< 3n, tp ≥ 70%, total bilirubin \< 1,5 n, creatinine in the blood ≤ 110 micromoles/l. * normal clearance of creatinine, according to cockroft and gault's formulae. * calcemia : normal or anomaly without clinical meaning. * well-informed written consent, signed by the patient. exclusion criteria: * uncontrolled cerebral known metastasis * all former chemotherapy administration during 5 years between inclusion * other cancer (except baso-cellular cancer of skin correctly treated, or cancerous disease considered with good prognosis and on remission until 5 years at least) * uncontrolled cardiac insufficiency or all other severe and uncontrolled pathology. * peripheric neuropathy ≥ grade 2 oms * anormal audiogram * patient difficult to follow for geographical, psychological or family reasons. * persons protected by law.

Keywords: genital neoplasms, male
cgm use in covid19 patients (infection with severe acute respiratory syndrome coronavirus 2 (sars-cov-2))

Conditions: Diabetes Mellitus; Covid19

Summary: the purpose of this research is to determine if cgm (continuous glucose monitors) used in the hospital in patients with covid-19 and diabetes treated with insulin will be as accurate as point of care (poc) glucose monitors. also if found to be accurate, cgm reading data will be used together with poc glucometers to dose insulin therapy.

study participation involves placement of a continuous glucose monitor (cgm) on the abdomen of hospitalized patients who have a diagnosis of covid19. the cgm will measure glucose levels every 5 minutes which will be accessible for viewing using a receiver phone placed outside the patient's room and/or an ipad located at the nursing station. alarm limits for hypoglycemia and hyperglycemia will be set on the receiver phone for nursing staff to review. these alarms settings will vary depending on whether the patient is on iv insulin infusion vs. subcutaneous (sq) insulin. the number of glucose checks required with these two types of insulin varies significantly and requires separate handling. hospital glucometers will be used to confirm the accuracy of cgm readings during an initial "adjustment phase" of the study. if cgms are found to be accurate, then finger-stick glucometer check frequency will be decreased, and some of the cgm values will be used to dose insulin therapy during the "utilization phase" of the study. the instructions for these phases will differ for patients on iv insulin infusion vs. sq insulin infusion and are detailed in separate protocols. nursing staff will choose the appropriate protocol at the time of cgm placement based on the type of insulin the patient is receiving. different patient variables (demographics, comorbidities, labs and vitals, administered medications) will be collected from electronic health record and will be evaluated to determine if they interfere with cgm readings. at the time of discharge, patients will receive a survey regarding satisfaction with the use of cgm monitors to manage their diabetes during their inpatient stay.

Eligibility criteria:
inclusion criteria: * patients 18 years or older. * patients with diagnosis of covid-19 respiratory infection. * patient with recent positive sars-cov2 infection and still positive polymerase chain reaction (pcr) admitted of non-respiratory diagnoses. * diagnosis of diabetes mellitus type 1 or type 2. * diagnosis of medication (steroid) induced hyperglycemia (persistent glucose more than 180 mg/dl). * taking insulin either sq or iv. exclusion criteria: * patient in shock. * patient intubated on mechanical ventilation. * patient placed on extracorporeal membrane oxygenation (ecmo). * patient taking hydroxyurea. * patient taking more than 4g of acetaminophen in 24 hours or more than 1g acetaminophen in 6 hours. * pregnant or nursing female patients. * patients with skin lesions at the application site that may interfere with placement of the sensor. * patients with known allergy to medical grade adhesive.
study in leucocytes from patients with type 1 and type 2 diabetes genetic markers of inflammation and oxidative stress (télomères/ candidate genes) according to the type a or type b behavior profile

Conditions: Patients With Type 1 or Type 2 Diabetes; Patients With a Type A or B Behaviour Profile

Summary: this study will include 100 patients with type 1 and type 2 diabetes, split into 2 groups of 50 patients according to their behaviour type, and their adaptation to different factors of stress encountered in their lives: * the first group will consist of patients with a characteristic type a behaviour profile, that is to say patients with a "proactive, impatient" behaviour pattern * the second group will consist of patients with a characteristic type b behaviour profile that is to say patients with a "calm, slow" behaviour pattern the objective is to know if the different behaviour patterns are associated with distinct biological markers likely to influence the evolution of the diabetes. participation in this study will be approximately 1h30, patients will participate once only: 1. they will answer simple questions about their disease and then complete 3 questionnaires each with 14 items. 2. they will meet a clinical psychologist for an interview lasting approximately 45 minutes recorded on an audio recorder. the consultation will be used to seek links between the psyche and the disease. 3. they will provide one blood sample of 12 ml (equivalent to a soup spoon) drawn in the morning.


Eligibility criteria:
inclusion criteria: * patients who have provided written informed consent * patients with type 1 or type 2 diabetes * patient admitted for a consultation, as out or in-patients to the endocrinology-diabetology-metabolic diseases department of dijon chu * patient \> 18 years * patient with either a characteristic type a behaviour profile (bortner \> 210), or a characteristic type b behaviour profile (bortner\<154) exclusion criteria: * persons not covered by national health insurance * adults under guardianship or wards of court or not intellectually independent * patients without diabetes * patients with a mixed a/b behaviour profile (154\< bortner score \<210) * pregnant or breast-feeding women
sitagliptin versus sulphonylurea in type 2 diabetes during ramadan

Conditions: Diabetes; Hypoglycemia

Summary: this study will assess if sitagliptin addition to metformin or glitazone is better than current sulphonylurea based treatments during ramadan. the rationale is that sitagliptin offers metabolic advantages primarily with the low incidence of hypoglycemia over current sulphonylurea based treatments.

to define metabolic alterations during ramadan: 1. primary end point: occurrence of hypoglycemia. the patients will record hypoglycaemic episodes in a self-monitoring diary together with blood glucose values. 2. secondary endpoints: body weight, fasting blood sugar (fbs), glycosylated haemoglobin (hba1c)/fructosamine, triglycerides (tg), total cholesterol (tc), low-density lipoprotein-cholesterol (ldl-c) and high density lipoprotein-cholesterol (hdl-c). 3. a subgroup will undergo cgms assessment to define glycaemic excursions during and after fasting.

Eligibility criteria:
inclusion criteria: 1. muslim men and women with type 2 diabetes. 2. age 18-78 years 3. intending to fast during the month of ramadan 4. on oral antihyperglycemic agents (sulphonylurea based/combination therapy) exclusion criteria: 1. patient with hypersensitivity or contraindication to sitagliptin treatment 2. patient with ckd (creatinine clearance \<50 ml/min) 3. patients who have participated in another intervention study in the last 2 months 4. patients who do not give informed consent 5. pregnant or breast feeding women. 6. patients on insulin 7. patients with severe liver disease

Keywords: diabetes hypoglycemia ramadan fasting
a suggested rehabilitation protocol for the treatment of c-shape scoliosis

Conditions: Idiopathic Scoliosis; Scoliosis Idiopathic; Rehabilitation; C-shape

Summary: this study aims to compare the effectiveness of mechanical traction and 3d apical vertebral mobilization and active exercises on cobb's angle, spinal rom, and function in patients with c-shaped scoliosis.

scoliosis is a skeletal issue causing asymmetries, leading to functional disruptions. common symptoms include uneven eye tilt, drop asloped shoulder, and muscle imbalances. these changes can affect the patient's physical appearance and psychological state. current treatments have shown suboptimal results due to the lack of accepted scientific theories for idiopathic scoliosis. therefore, a new therapeutic approach is needed to provide novel insights and improve treatment outcomes. this underscores the need for a more comprehensive approach to scoliosis treatment.

Eligibility criteria:
inclusion criteria: 1. adult individuals aged 18 to 30 years (after complete ossification and before the start of the ageing process and joint changes) as mentioned in studies. 2. thoracolumbar scoliosis with cobb angle between 10 to 30 degrees because a curve below 10 degrees has no effect and above 30 is indicated for surgery. exclusion criteria: 1. history of orthopaedic surgeries. 2. history of road traffic accidents (rta). 3. myopathy. 4. true leg length discrepancy. 5. neuropathy. 6. mental disorders. 7. bone tumor. 8. heart disease or circulatory problems. 9. early osteoporosis.
clinical trial comparing taurolocktmhep100 (taurolidine 1.35%) and 0.9% saline as prevention of recurrent catheter-related bloodstream infections

Conditions: Catheter Related Blood Stream Infections; Intestinal Failure

Summary: the purpose of the trial is to compare two catheter lock solutions (active: 1.35% taurolidine and placebo: 0.9% saline), on the occurence of catheter related blood stream infection, in patients with intestinal failure and a central venous catheter for home parenteral support.

patients with long-term intestinal failure rely on home parenteral support (hps) delivered through a central venous catheter(cvc). catheter related blood stream infections(crbsi) are a frequent complication leading to increased morbidity, hospital admissions, cost, and risk of repeated replacement of the cvc. the infections often originate from contamination of the catheter hub, and growth of microorganisms on the inner lumen of the catheter imbedded in a biofilm. to prevent infections good hygiene guidelines and the use of a catheter lock solution is applied. the primary objective is to compare two catheter lock solutions, 1,35% taurolidine and 0.9% saline, on the occurence of recurrent crbsis. the secondary objectives are to compare the two devices according to other catheter-related complications, adverse events and costs. patients with at least one prior crbsi is included. patients instill the solution in their cvc after each infusion of hps, with a minimum of three times per week, depending on their individual hps programme. before the blinded randomization the patients will be paired according to age and stratified according to prior crbsi incidence. duration of the instillation will be 24 months.

Eligibility criteria:
inclusion criteria: patients receiving hps at the department of medical gastroenterology, rigshospitalet, who have at least one prior crbsi and thereby demonstrated susceptibility towards developing crbsi while on hps and the following: 1. signed informed consent form 2. has a single-lumen subcutaneously tunneled cvc 3. has been at least 3 weeks since termination of the antibiotic treatment for their last crbsi exclusion criteria: patients who: 1. have a known hypersensitivity/allergy to taurolocktmhep 100 or heparin and/or their excipients 2. are pregnant, lactating or nursing

Keywords: taurolidine catheter-related bloodstream infections intestinal failure
a prospective, open-label study of [68ga]ga-dota-tate in patients with neuroendocrine neoplasms (nens) and healthy volunteers in japan

Conditions: Neuroendocrine Neoplasms

Summary: the purpose of this study is to evaluate the diagnostic performance of \[68ga\]ga-dota-tate positron emission tomography (pet)/computerized tomography (ct) imaging compared with conventional imaging (cim) as standard of truth in patients with neuroendocrine neoplasms (nens) and healthy volunteers (hvs). the data from this study will provide the evidence for diagnosis of \[68ga\]ga-dota-tate pet/ct imaging in patient with nens in japan.

all enrolled participants will undergo \[68ga\]ga-dota-tate pet/ct imaging. \[68ga\]ga-dota-tate will be administered intravenously at a dose of 2 mega-becquerel (mbq) / kilogram (kg) (0.054 millicurie (mci)/kilogram (kg)) of body weight up to a maximum total dose of 200 mbq (5.4 mci), and pet/ct imaging will be acquired 40 to 90 minutes after the intravenous administration of \[68ga\]ga-dota-tate. * duration of screening period is up to 35 days * imaging period will be completed within one day followed by safety follow up visit (day 8) after imaging day (day 1)

Eligibility criteria:
key inclusion criteria: 1. signed informed consent must be obtained prior to participation in the study 2. participants must be adults \>= 18 years of age 3. ecog performance status 0-2 4. for patient with nens only: participants with confirmed nens based on histopathology, imaging and other relevant examination, or with suspected nens which localization cannot be confirmed by cim 5. for hvs only: male or female participant in good health condition as determined by no clinically significant findings from medical history, physical examination, vital signs, lab test and ecg 6. women of childbearing potential must have a negative urine or blood pregnancy test. key exclusion criteria: 1. inability to complete the needed investigational and conventional imaging due to any reason (severe claustrophobia, inability to lie still for the entire imaging time, etc.) 2. any additional medical condition, serious intercurrent illness, concomitant cancer or other extenuating circumstance that, in the opinion of the investigator, would indicate a significant risk to safety or impair study participation 3. known allergy, hypersensitivity, or intolerance to \[68ga\]ga-dota-tate and \[111in\]in-pentetreotide 4. therapeutic use of any somatostatin analogue except for the following washout period * short-acting analogs of somatostatin can be used up to 24 hours before injection of \[68ga\]ga-dota-tate. * long-acting analogs of somatostatin can be used up to 28 days before injection of \[68ga\]ga-dota-tate. 5. prior administration of a radiopharmaceutical unless 10 or more half-lives have elapsed before injection of \[68ga\]ga-dota-tate 6. use of other investigational drugs within 30 days before screening 7. participants who are pregnant. 8. participants who are lactating.

Keywords: [68ga]ga-dota-tate neuroendocrine neoplasms (nens) positron emission tomography (pet) computerized tomography (ct) pet/ct diagnostic performance sensitivity specificity
stricture definition and treatment (strident) drug therapy study

Conditions: Crohn Disease; Inflammatory Bowel Diseases; Stricture; Bowel

Summary: two thirds of patients with crohn's disease require intestinal surgery at some time in their life. intestinal strictures, that is narrowing of the bowel due to inflammation and scarring, are the most common reason for surgery. despite the high frequency, associated disability, and cost there are no are no treatment strategies that aim to improve the outcome of this disease complication. the strident (stricture definition and treatment) studies aim to develop such strategies.

prospective randomised controlled study. patients with crohn's disease who have symptomatic inflammatory intestinal strictures will be randomised to receive standard drug therapy (anti-tnf monotherapy at standard dose) or intensive drug therapy (intense anti-tnf dose induction and escalation for continued inflammation in combination with thiopurine) for 12 months.

Eligibility criteria:
inclusion criteria: * inflammatory bowel disease patients with intestinal stricture(s) identified on ct, mri or endoscopy. exclusion criteria: * acute bowel obstruction requiring urgent surgical intervention * deemed by treating physician to have high risk of acute bowel obstruction * concurrent active perianal sepsis * internal fistulising disease in association with strictures (entero-enteric stulas) * low rectal or anal strictures * evidence of dysplasia or malignancy from stricture biopsies or adjacent mucosal biopsies * patients for whom endoscopy is not suitable due to co-morbidities or clinical state * inability to give informed consent * suspected perforation of the gastrointestinal tract * pregnancy * inability to undergo mri small bowel due to a contraindication.

Keywords: crohn disease inflammatory bowel disease intestinal stricture